Reference Laboratory Genetics

referencelaboratory.es

Since its foundation in 1975, Reference Laboratory has established itself as one of the leading European laboratories in special analysis. We are the largest laboratory in Europe (15.000m2) and we currently collaborate with more than 400 hospitals and over 1,000 laboratories around the world. Reference Laboratory Genetics is our Genetics and Molecular Diagnostics Division.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

BIO-MANUFACTURING PARTNER BIOELPIDA COMPLETES NEXT PHASE OF BVX-0918 GMP PRODUCTION FOR EU CLINICAL STUDY

BioVaxys | June 09, 2022

news image

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that its Lyon, France-based bioproduction partner, BioElpida ("BioElpida"), has completed the creation of multiple OVCAR-3 cell banks as the next step in the GMP manufacturing process development for BVX-0918, BioVaxys' vaccine for treatment of platinum-resistant ovarian cancer. The OVCAR-3 cell line is mandatory for creating the identity ass...

Read More

Cell and Gene Therapy

GRACELL BIOTECHNOLOGIES UNVEILS INNOVATION CENTER IN U.S.

Gracell Biotechnologies Inc | January 13, 2022

news image

Gracell Biotechnologies Inc. a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that its newly established research facility, the Innovation Center, is scheduled to open in San Diego, California, during the first quarter of 2022. As a pivotal part of Gracell's global strategy, the company is fully committed to expanding its operations in the U.S. to enhance and ...

Read More

Medical

SESEN BIO PARTNERS WITH HIKMA PHARMACEUTICALS FOR THE REGISTRATION AND COMMERCIALIZATION OF VICINEUM

Sesen Bio | December 02, 2020

news image

Sesen Bio, a late-stage clinical organization creating focused on combination protein therapeutics for the therapy of patients with cancer, and Hikma Pharmaceuticals, a worldwide pharmaceutical organization and driving permitting partner in the Middle East and North Africa ("MENA") area spend significant time in the turn of events and commercialization of an expansive scope of great medicines, today declared that the organizations have gone into exclusive licensing agreement for the re...

Read More

Cell and Gene Therapy, Industrial Impact

ALDEVRON LAUNCHES TYPE-V CRISPR NUCLEASE, EURECA-V™ MAD7®

Aldevron | January 20, 2023

news image

Aldevron®, a worldwide leader in the custom development and production of plasmid DNA, RNA, and proteins for the biotech sector, recently announced the launch of Eureca-V™ nuclease. Eureca-V™, licensed from Inscripta®, is the wild-type MAD7® CRISPR Type-V nuclease at research grade, with GMP to follow. The launch of Aldevron's Eureca-V nuclease at advanced therapies week expands the toolkit of accessible CRISPR nucleases for therapeutic, di...

Read More
news image

Medical

BIO-MANUFACTURING PARTNER BIOELPIDA COMPLETES NEXT PHASE OF BVX-0918 GMP PRODUCTION FOR EU CLINICAL STUDY

BioVaxys | June 09, 2022

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that its Lyon, France-based bioproduction partner, BioElpida ("BioElpida"), has completed the creation of multiple OVCAR-3 cell banks as the next step in the GMP manufacturing process development for BVX-0918, BioVaxys' vaccine for treatment of platinum-resistant ovarian cancer. The OVCAR-3 cell line is mandatory for creating the identity ass...

Read More
news image

Cell and Gene Therapy

GRACELL BIOTECHNOLOGIES UNVEILS INNOVATION CENTER IN U.S.

Gracell Biotechnologies Inc | January 13, 2022

Gracell Biotechnologies Inc. a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that its newly established research facility, the Innovation Center, is scheduled to open in San Diego, California, during the first quarter of 2022. As a pivotal part of Gracell's global strategy, the company is fully committed to expanding its operations in the U.S. to enhance and ...

Read More
news image

Medical

SESEN BIO PARTNERS WITH HIKMA PHARMACEUTICALS FOR THE REGISTRATION AND COMMERCIALIZATION OF VICINEUM

Sesen Bio | December 02, 2020

Sesen Bio, a late-stage clinical organization creating focused on combination protein therapeutics for the therapy of patients with cancer, and Hikma Pharmaceuticals, a worldwide pharmaceutical organization and driving permitting partner in the Middle East and North Africa ("MENA") area spend significant time in the turn of events and commercialization of an expansive scope of great medicines, today declared that the organizations have gone into exclusive licensing agreement for the re...

Read More
news image

Cell and Gene Therapy, Industrial Impact

ALDEVRON LAUNCHES TYPE-V CRISPR NUCLEASE, EURECA-V™ MAD7®

Aldevron | January 20, 2023

Aldevron®, a worldwide leader in the custom development and production of plasmid DNA, RNA, and proteins for the biotech sector, recently announced the launch of Eureca-V™ nuclease. Eureca-V™, licensed from Inscripta®, is the wild-type MAD7® CRISPR Type-V nuclease at research grade, with GMP to follow. The launch of Aldevron's Eureca-V nuclease at advanced therapies week expands the toolkit of accessible CRISPR nucleases for therapeutic, di...

Read More

Resources

resource image

Industry Outlook

Biopharmaceutical Sector

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us